Is Yasmin (drospirenone and ethinyl estradiol) safe for females with migraines with brainstem aura?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Yasmin is Absolutely Contraindicated in Women with Migraine with Brainstem Aura

No, Yasmin (drospirenone/ethinyl estradiol) is not safe for females with migraines with brainstem aura and should never be prescribed in this population due to a 6-fold increased risk of ischemic stroke. 1

Why Combined Hormonal Contraceptives Are Contraindicated

Women with migraine with aura who use combined hormonal contraceptives (CHCs) like Yasmin face a 6.1-fold increased risk of ischemic stroke (95% CI 3.1-12.1) compared to women with neither risk factor. 1 This represents an absolute contraindication according to multiple guideline societies. 2, 3

Baseline Stroke Risk in Migraine with Aura

  • Women with migraine with aura already have a 2.5-fold increased baseline risk of ischemic stroke (RR 2.51; 95% CI 1.52-4.14) before any hormonal exposure. 2
  • This baseline risk translates to approximately 4 additional intracranial hemorrhage events per 10,000 women per year. 4
  • Women with high migraine frequency (>weekly attacks) face even higher stroke risk (HR 4.25; 95% CI 1.36-13.29). 2

Compounding Effect of Estrogen

  • The combination of migraine with aura and CHCs creates a synergistic, not merely additive, stroke risk. 1
  • This risk is particularly pronounced in women under age 45 (RR 3.65; 95% CI 2.21-6.04). 2, 3
  • The presence of additional risk factors like smoking creates catastrophic stroke risk (RR 9.03; 95% CI 4.22-19.34). 2, 5, 3

Brainstem Aura: A Particularly High-Risk Subtype

Brainstem aura represents an especially concerning migraine subtype because it involves posterior circulation symptoms. Women with migraine with aura have a 13.7-fold increased prevalence of subclinical infarcts in the posterior circulation (95% CI 1.7-112). 4 The association with cerebellar lesions is particularly strong in women (OR 1.9; 95% CI 1.4-2.6). 4

  • Basilar hypoplasia and posterior circulation variants are statistically associated with migraine with aura (OR 9.2; 95% CI 2.3-37.2). 4
  • These anatomical variants in the brainstem circulation make estrogen exposure even more dangerous. 4

Guideline Consensus

  • The American Heart Association/American Stroke Association explicitly recommends against using estrogen-containing contraceptives in individuals with migraine with aura. 3
  • The American College of Obstetricians and Gynecologists and American Headache Society both classify CHCs as contraindicated in migraine with aura due to increased stroke risk. 3
  • This contraindication applies regardless of estrogen dose, though the evidence base comes primarily from higher-dose formulations. 6

Common Pitfall: Dose Misconceptions

Some clinicians mistakenly believe that ultra-low-dose formulations (<20 μg ethinyl estradiol) are safe in migraine with aura. 7, 8 However:

  • The 6-fold stroke risk data includes modern low-dose formulations. 1
  • No adequately powered studies have demonstrated safety of any estrogen dose in women with migraine with aura. 6
  • The absolute stroke risk remains low but is unacceptably elevated given safer contraceptive alternatives exist. 6

Safe Contraceptive Alternatives

Progestin-only methods carry no increased stroke risk and are the preferred contraceptive approach: 2

  • Levonorgestrel intrauterine system (IUD)
  • Etonogestrel implant (Nexplanon)
  • Progestin-only pills (norethindrone)
  • Depot medroxyprogesterone acetate (Depo-Provera)

Barrier methods and copper IUD are also safe options. 2

Critical Action Items

  • Immediately discontinue Yasmin if already prescribed. 2
  • Screen for and eliminate all modifiable stroke risk factors, particularly smoking. 2, 5
  • Initiate migraine prophylaxis (propranolol 80-160 mg daily or topiramate 50-100 mg daily) to reduce aura frequency and baseline stroke risk. 2, 5
  • Educate the patient on stroke warning signs and how to distinguish them from typical aura (sudden vs. gradual onset, simultaneous vs. successive symptoms). 2
  • Transition to progestin-only contraception if hormonal contraception is desired. 2

References

Guideline

HRT and Migraine with Aura

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Gender-Affirming Estrogen Therapy in Migraine with Aura

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Migraine with Aura Management in Stroke Survivors

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Combined hormonal contraceptives and migraine: An update on the evidence.

Cleveland Clinic journal of medicine, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.